1252 J. Am. Chem. Soc., Vol. 122, No. 7, 2000
D’Souza et al.
containing furanose residues,1-3 among the most important are
the mycobacteria.1 This genus of bacteria contains a number of
species, including the well-known human pathogens Mycobac-
terium tuberculosis and Mycobacterium leprae, respectively the
causes of tuberculosis and leprosy. In recent years infection by
other members of this genus have become health threats. Most
notable among these are Mycobacterium aVium infections, which
are now commonplace in AIDS patients.5 Although mycobac-
terial diseases have attracted renewed attention in recent years
because of their increasing incidence in the western world6 and
the emergence of drug-resistant strains,7 these diseases have been
a constant health threat worldwide for decades. For example,
over a third of the world’s population is estimated to be infected
with M. tuberculosis, and tuberculosis remains the single most
lethal bacterial disease, resulting in over 3 million deaths each
year.8
The treatment of mycobacterial diseases is difficult, requiring
adherence to a several-month regimen of antibiotics.7,9,10 Such
long treatments are necessary, in large part, as a result of the
incredible thickness and impermeability of the cell wall complex,
which prevents the effective passage of drugs into the organ-
ism.1,7,11 The morphology of the cell wall is unique to Myco-
bacteria and other members of the Actinomycetes family, and
the two major polysaccharide components are an arabinogalactan
(AG) and a lipoarabinomannan (LAM) in which all of the
galactose and arabinose residues are present in the furanose
form.1 The organism’s ability to make these polymers is critical
to its survival, and it has been shown that one of the drugs often
used to treat tuberculosis (ethambutol) acts by inhibiting the
biosynthesis of the arabinan portions of the AG and LAM.12
Figure 1. Hexaarabinoside motif (1) found at the nonreducing termini
of mycobacterial arabinogalactan (AG) and lipoarabinomannan (LAM).
binding proteins.15 In the AG, these same hydroxyl groups are
esterified with mycolic acids, branched, long-chain fatty ac-
ids.1,11,14 Through the tight packing of the alkyl chains, the
mycolic acids form a protective hydrophobic facade that in some
cases is nearly crystalline.11,16
It is unknown why mycobacteria synthesize cell wall polysac-
charides containing predominantly furanose residues. However,
it has been suggested that the protection afforded to the organism
by the tightly packed mycolic acids in the AG is one of the
reasons why mycobacteria have evolved to produce polyfura-
nosides and not polypyranosides.11 Polysaccharides containing
furanose rings are expected to be more conformationally flexible
than their counterparts composed of pyranose residues,17 and
thus the former would better allow the mycolic acids to align
in the proper orientation for side-by-side packing. This proposal
is, however, without any experimental support.
Identifying new antibiotics for the treatment of mycobacterial
diseases is an area of current interest,10,18 and inhibitors of
mycobacterial arabinosyltransferases are ideal synthetic targets.19
However, progress in this field has been hampered by the limited
amount of detailed information that is available concerning the
biosynthesis of mycobacterial arabinan.20 To some degree, this
is due to the lack of synthetic substrates that can be used for
fundamental biochemical studies leading to the isolation and
A detailed structural model of the mycobacterial cell wall is
now available.1,13,14 The terminal ends of both AG and LAM
are capped with the hexasaccharide motif 1 (Figure 1), which
is linked to the remainder of the polymer via an R-(1f5)-linked
linear chain of arabinofuranose residues. Hexasaccharide 1 in
turn serves as the attachment site for other functionalities present
in the cell wall. These groups are located at the periphery of
the cell wall complex and are therefore the interface between
the microorganism and its environment. In LAM, the primary
hydroxyl groups in 1 are often substituted with mannopyranosyl
oligosaccharides, which have been implicated in the initial stages
of infection through their interaction with human mannose-
(5) (a) Horsburgh, C. R., Jr. J. Infect. Dis. 1999, 179, S461. (b) Wahl,
S. M.; Greenwell-Wild, T.; Peng, G.; Hale-Donze, H.; Orenstein, J. M. J.
Infect. Dis. 1999, 179, S457. (c) Armstrong, W. S.; Katz, J. T.; Kazanjian,
P. H. Clin. Infect. Dis. 1999, 28, 341.
(6) (a) Opravil, M. Infection 1997, 25, 56. (b) Millard, F. J. J. Royal
Soc. Med. 1996, 89, 497. (c) Efferen, L. S.; Hyman, C. L. Curr. Opin.
Pulm. Med. 1996, 2, 236.
(7) Blanchard, J. S. Annu. ReV. Biochem. 1996, 65, 215.
(8) Dolin, P. J.; Raviglione, M. C.; Kochi, A. Bull. World Health Org.
1994, 72, 213.
(15) (a) Schlesinger, L. S. Curr. Topics Microbiol. Immunol. 1996, 215,
71. (b) Schlesinger, L. S.; Hull, S. R.; Kaufman, T. M. J. Immunol. 1994,
152, 4070. (c) Schlesinger, L. S.; Kaufman, T. M.; Iyer, S.; Hull, S. R.;
Marchiando, L. K. J. Immunol. 1996, 157, 4568. (d) Kang, B. K.;
Schlesinger, L. S. Infect. Immun. 1998, 66, 2769.
(16) (a) Jarlier, V.; Nikaido, H. FEMS Microbiol. Lett. 1994, 123, 11.
(b) Liu, J.; Barry, C. E., III; Besra, G. S.; Nikaido, H. J. Biol. Chem. 1996,
271, 29545.
(17) Westhof, E.; Sundaralingam, M. J. Am. Chem. Soc. 1983, 105, 970.
(18) Barry, C. E., III. Biochem. Pharm. 1997, 54, 1165.
(9) Mitchison, D. A. Tubercle 1985, 66, 219.
(10) Young, D. B.; Duncan, K. Annu. ReV. Microbiol. 1995, 49, 641.
(11) Connell, N. D.; Nikaido, H. Membrane permeability and transport
in Mycobacterium tuberculosis. In Tuberculosis: Pathogenesis, Protection
and Control; Bloom, B. R., Ed.; American Society for Microbiology,
Washington, D.C., 1994; p 333.
(12) (a) Mikusova´, K.; Slayden, R. A.; Besra, G. S.; Brennan, P. J.
Antimicrob. Agents Chemother. 1995, 39, 2484. (b) Deng, L.; Mikusova´,
K.; Robuck, K. G.; Scherman, M.; Brennan, P. J.; McNeil, M. R. Antimicrob.
Agents Chemother. 1995, 39, 694. (c) Khoo, K.-H.; Douglas, E.; Azadi, P.;
Inamine, J. M.; Besra, G. S.; Mikusova´, K.; Brennan, P. J.; Chatterjee, D.
J. Biol. Chem. 1996, 271, 28682.
(19) (a) Bouix, C. B.; Bisseret, P.; Eustache, J. Tetrahedron Lett. 1998,
39, 825. (b) Maddry, J. A.; Bansal, N.; Bermudez, L. E.; Comber, R. N.;
Orme, I. M.; Suling, W. J.; Wilson, L. N.; Reynolds, R. C. Bioorg. Med.
Chem. Lett. 1998, 8, 237. (c) Lee, R. E.; Smith, M. D.; Nash, R. J.; Griffiths,
R. C.; McNeil, M.; Grewal, R. K.; Yan, W.; Besra, G. S.; Brennan, P. J.;
Fleet, G. W. J. Tetrahedron Lett. 1997, 38, 6733.
(20) For some recent studies on arabinan biosynthesis in mycobacteria,
see: (a) Lee, R. E.; Brennan, P. J.; Besra, G. S. Glycobiology 1997, 7,
1121. (b) Woluka, B.; McNeil, M. R.; deHoffman, E.; Chojnacki, T.;
Brennan, P. J. J. Biol. Chem. 1994, 269, 23328. (c) Scherman, M. S.; Kalbe-
Bournonville, L.; Bush, D.; Xin, Y.; Deng, L.; McNeil, M. J. Biol. Chem.
1996, 271, 29652. (d) Lee, R. E.; Mikusova´, K.; Brennan, P. J.; Besra, G.
S. J. Am. Chem. Soc. 1995, 117, 11829. (e) Xin, Y.; Lee, R. E.; Scherman,
M. S.; Khoo, K. H.; Besra, G. S.; Brennan, P. J.; McNeil, M. Biochim.
Biophys. Acta 1997, 1335, 231.
(13) Besra, G. S.; Khoo, K.-H.; McNeil, M. R.; Dell, A.; Morris, H. R.;
Brennan, P. J. Biochemistry 1995, 34, 4257.
(14) Lee, R. E.; Brennan, P. J.; Besra, G. S. Curr. Topics Microbiol.
Immunol. 1996, 215, 1.